2,512 Intuitive Surgical, Inc. $ISRG Shares Purchased by Schaper Benz & Wise Investment Counsel Inc. WI

Schaper Benz & Wise Investment Counsel Inc. WI lifted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,642 shares of the medical equipment provider’s stock after buying an additional 2,512 shares during the period. Intuitive Surgical makes up 1.0% of Schaper Benz & Wise Investment Counsel Inc. WI’s portfolio, making the stock its 29th biggest position. Schaper Benz & Wise Investment Counsel Inc. WI’s holdings in Intuitive Surgical were worth $16,933,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of ISRG. Plato Investment Management Ltd purchased a new stake in Intuitive Surgical during the 2nd quarter valued at $4,315,000. Sycomore Asset Management purchased a new position in shares of Intuitive Surgical in the 4th quarter worth $10,730,000. Hikari Power Ltd purchased a new position in shares of Intuitive Surgical in the 2nd quarter worth $5,619,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Intuitive Surgical in the second quarter worth $14,316,000. Finally, Xponance LLC increased its position in Intuitive Surgical by 5.3% during the fourth quarter. Xponance LLC now owns 91,787 shares of the medical equipment provider’s stock valued at $51,984,000 after acquiring an additional 4,648 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Price Performance

ISRG stock opened at $423.96 on Friday. Intuitive Surgical, Inc. has a 1-year low of $328.57 and a 1-year high of $603.88. The company has a market capitalization of $149.78 billion, a price-to-earnings ratio of 48.56, a PEG ratio of 3.13 and a beta of 1.46. The business has a 50 day simple moving average of $386.36 and a two-hundred day simple moving average of $411.26.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The firm had revenue of $2.89 billion for the quarter, compared to analysts’ expectations of $2.83 billion. During the same quarter last year, the business posted $1.81 earnings per share. The company’s revenue for the quarter was up 18.4% compared to the same quarter last year. Sell-side analysts anticipate that Intuitive Surgical, Inc. will post 8.87 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ISRG. BMO Capital Markets reissued an “outperform” rating on shares of Intuitive Surgical in a report on Monday, July 20th. BNP Paribas Exane upgraded shares of Intuitive Surgical to an “outperform” rating in a research note on Tuesday, July 28th. Bank of America dropped their price objective on shares of Intuitive Surgical from $520.00 to $515.00 in a report on Friday, June 12th. Evercore set a $430.00 target price on shares of Intuitive Surgical in a report on Monday, July 6th. Finally, Oppenheimer upgraded shares of Intuitive Surgical from a “market perform” rating to an “outperform” rating and set a $500.00 price target on the stock in a research report on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $502.53.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, Director Amy L. Ladd sold 400 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $379.00, for a total transaction of $151,600.00. Following the completion of the transaction, the director owned 251 shares of the company’s stock, valued at $95,129. This represents a 61.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark Brosius sold 77 shares of Intuitive Surgical stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $375.57, for a total value of $28,918.89. Following the completion of the sale, the executive vice president directly owned 881 shares in the company, valued at $330,877.17. This trade represents a 8.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,370 shares of company stock valued at $4,891,989 in the last ninety days. Corporate insiders own 0.60% of the company’s stock.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Barclays upgraded Intuitive Surgical to “strong buy” and initiated coverage at “overweight,” citing the company’s high-quality healthcare-equipment business despite a softer medical-device market. The bullish rating provides a near-term catalyst for the shares. Barclays initiates coverage of Intuitive Surgical
• Positive Sentiment: Piper Sandler also assigned a Buy rating, reinforcing favorable sell-side sentiment around ISRG. Intuitive Surgical gets a Buy from Piper Sandler
• Positive Sentiment: The company’s single-port robotic platform is gaining momentum, with rising procedures, utilization and system placements. Expanding medical indications and international adoption could support longer-term revenue growth. Can ISRG’s Single-Port Platform Become the Next Billion-Dollar Franchise?
• Neutral Sentiment: Analysts’ average recommendation remains bullish, but commentary warns that consensus ratings can be overly optimistic and that ISRG’s valuation leaves limited room for disappointment. Is Intuitive Surgical a Buy as Wall Street Analysts Look Optimistic?
• Neutral Sentiment: A reported short-interest figure of zero shares and a zero-day days-to-cover ratio suggests the latest short-interest data may be incomplete or erroneous, limiting its usefulness as a trading signal.
• Negative Sentiment: Jim Cramer expressed concern that Johnson & Johnson and other rivals could intensify competition in robotic surgery, potentially pressuring ISRG’s long-term market position. Intuitive Surgical and JNJ Give Jim Cramer More Than Valuation to Consider

About Intuitive Surgical

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company’s products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.